Smartool Private Space

We take care patients with coronary heart disease


SMARTool project aims to develop a platform based on cloud technology for clinical decision support to the management of patients with coronary artery disease (CAD).

Patient-specific CAD stratification

Existing clinical stratification models (such as Framingham, Genders, GES – Gene Expression Score), based on traditional as well as on emerging risk factors, will be implemented by patient genotyping and phenotyping (cellular/molecular markers) and tested by retrospective (baseline) and prospective clinical data (follow-up) from the EVINCI project population to stratify patients with non-obstructive CAD, obstructive CAD and those without CAD.

Site specific plaque progression prediction

The existing multiscale and multilevel models for plaque progression prediction of the ARTreat project will be refined using additional genotyping and phenotyping features and tested by retrospective and prospective non-invasive CCTA imaging data plus non-imaging patient-specific information collected at follow-up from the EVINCI population.

Patient-specific CAD diagnosis and CAD-related CHD treatment

Patient-specific therapeutical management will be provided, such as life style changes, standard or high intensity medical therapy. Moreover, a virtual angioplasty tool will provide to the interventional cardiologist the optimal stent type(s) and select site(s) for appropriate stent deployment.


Lipidomics on about 600-700 plasma samples will be performed using mass spectrometry.

Omics analysis

Exome data generated will be analysed to reveal coding variants, including genetic alterations such as single nucleotide variants and short indels, Copy Number Variations (CNVs) including deletions and amplifications.

3D arterial reconstruction

Computed tomography is used for non-invasive imaging of coronary arteries and a platform is developed for automate 3D reconstruction.